Although c-Myc usually leads to the occurrence and development of malignant tumors (Iwakawa et al., 2011), it is difficult to be targeted by traditional small molecule drugs because c-Myc is a natural disordered protein and lacks available drug recognition sites (Sorolla et al., 2020). This evidence concerns the gene MYC and cancer.